Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

IDEXX Laboratories Inc (NASDAQ:IDXX)

179.36
Delayed Data
As of Jan 17
 +3.26 / +1.85%
Today’s Change
116.54
Today|||52-Week Range
180.20
+14.69%
Year-to-Date
IDEXX Launches Catalyst SDMA for Veterinary Renal Disorder
Jan 15 / Zacks.com - Paid Partner Content
Idexx Laboratories Inc (IDXX) Chairman, President & CEO Jonathan W Ayers Sold $9 mill...
Jan 11 / GuruFocus News - Paid Partner Content
Largest Insider Trades of the Week
Jan 12 / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close176.10
Today’s open177.14
Day’s range175.99 - 180.20
Volume548,140
Average volume (3 months)485,632
Market cap$15.4B
Data as of 4:00pm ET, 01/17/2018

Growth & Valuation

Earnings growth (last year)+19.02%
Earnings growth (this year)+32.37%
Earnings growth (next 5 years)+20.41%
Revenue growth (last year)+10.83%
P/E ratio58.2
Price/Sales6.00
Price/Book--

Competitors

----
NEOGNeogen Corp-0.19-0.32%
AAAPAdvanced Accelerator...+0.02+0.02%
MYGNMyriad Genetics Inc+1.05+2.93%
Data as of 4:00pm ET, 01/17/2018

Financials

Next reporting dateFebruary 1, 2018
EPS forecast (this quarter)$0.68
Annual revenue (last year)$1.8B
Annual profit (last year)$222.0M
Net profit margin12.51%

Profile

Sector
Health Technology
Industry
Medical Specialties
Chairman, President &
Chief Executive Officer
Jonathan W. Ayers
Chief Financial Officer, Treasurer &
Executive VP
Brian P. McKeon
Corporate headquarters
Westbrook, Maine

Forecasts